MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
33.90
+0.70
+2.11%
Pre Market: 34.71 +0.81 +2.39% 07:00 06/25 EDT
OPEN
33.51
PREV CLOSE
33.20
HIGH
36.00
LOW
33.51
VOLUME
2.32K
TURNOVER
0
52 WEEK HIGH
36.88
52 WEEK LOW
15.60
MARKET CAP
3.49B
P/E (TTM)
-52.8284
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Beam Therapeutics (BEAM)
TipRanks · 1d ago
Weekly Report: what happened at BEAM last week (0615-0619)?
Weekly Report · 3d ago
Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial
Simply Wall St · 5d ago
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
NASDAQ · 5d ago
The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonuria
Benzinga · 06/18 11:09
Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304
TipRanks · 06/18 11:05
Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304
PUBT · 06/18 11:00
BEAM THERAPEUTICS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BEAM-304 FOR THE TREATMENT OF PHENYLKETONURIA (PKU) BY THE UNITED STATES (U.S.) FOOD AND DRUG ADMINISTRATION
Reuters · 06/18 11:00
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.